Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis.
Over a 1-y period, 26 inpatients at the Jordan University Hospital in Amman were detected with bacteraemia (23 cases) or respiratory tract colonized with B. cepacia (3 cases). A combination of genetic identification and molecular typing has proved that all cases were caused by a single epidemic strain of B. cepacia genomovar IIIa. Nosocomial infections could be documented in 21/26 (81%) patients, mostly with severe underlying or malignant diseases other than cystic fibrosis, but the source of infection was undetected. The overall mortality related to infection with B. cepacia was 42%. All B. cepacia isolates were resistant to ampicillin, amikacin, carbenicillin and gentamicin; and mostly susceptible to piperacillin, chloramphenicol, cotri-moxazole, tetracycline, ceftazidime, and tazocin (62-88%). This study demonstrates the nosocomial and high fatality of B. cepacia genomovar IIIa in Jordanian patients suffering from diseases other than cystic fibrosis.
Shehabi
Asem A
AA
Department of Clinical Laboratories, Jordan University Hospital, Amman, Jordan. ashehabi@ju.edu.jo
Abu-Al-Soud
Waleed
W
Mahafzah
Azmi
A
Khuri-Bulos
Najwa
N
Abu Khader
Ilham
I
Ouis
Ibn-Sina
IS
Wadström
Torkel
T
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000453:epidemiology* / Q000382:microbiology; D019121:Burkholderia Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D016956:Burkholderia cepacia / Q000302:isolation & purification*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000453:epidemiology; D004269:DNA, Bacterial / Q000032:analysis; D004196:Disease Outbreaks; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D007597:Jordan / Q000453:epidemiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D016019:Survival Analysis
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial